phrykt

BeOne Medicines (ONC) debt: $836M

BeOne Medicines had $836M of long-term debt on Dec 31, 2025, including the part due within a year, down 17.8% from $1B a year earlier.

From BeOne Medicines's filings with the SEC · Read the filing · ONC stock page

BeOne Medicines debt by year

$630M2021$538M2022$886M2023$1B2024$836M2025

#954 of 2,129 US companies by debt · See the full ranking

Year endedDebtChange
Dec 31, 2025$836M-18%
Dec 31, 2024$1B+15%
Dec 31, 2023$886M+65%
Dec 31, 2022$538M-15%
Dec 31, 2021$630M–

Debt of similar companies

Companies in the same industry as BeOne Medicines, by SEC industry code, with the closest debt. Each name opens the same page for that company.

CompanyDebt, latest yearYear ended
Prestige Consumer Healthcare$1BDec 31, 2025
BeOne Medicines$836MDec 31, 2025
Sarepta Therapeutics$829MDec 31, 2025
Phibro Animal Health$624MDec 31, 2025
Amphastar Pharmaceuticals$620MDec 31, 2025
Biomarin Pharmaceutical$597MDec 31, 2025
INSMED$547MDec 31, 2025

Questions and answers

What is BeOne Medicines's debt?

BeOne Medicines had $836M of long-term debt on Dec 31, 2025, including the part due within a year, down 17.8% from $1B a year earlier.

Numbers as reported in BeOne Medicines's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology